Axsome Begins Phase III Study on Solriamfetol for ADHD in ChildrenZacks Investment Research • 07/08/26
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewsWire • 07/07/26
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even MoreThe Motley Fool • 07/06/26
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.The Motley Fool • 07/02/26
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewsWire • 06/26/26
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness MonthGlobeNewsWire • 06/18/26
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026GlobeNewsWire • 06/15/26
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS PipelineMarketBeat • 06/06/26
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific MeetingGlobeNewsWire • 06/04/26
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent LitigationGlobeNewsWire • 06/03/26
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness MonthGlobeNewsWire • 06/01/26
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual MeetingGlobeNewsWire • 05/26/26
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation LaunchMarketBeat • 05/12/26
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be DeniedSeeking Alpha • 05/04/26
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/04/26